FDA approval for capivasertib: and our new collaboration opportunities for industry partners 17 Nov 2023 The US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib? Find out more Show/Hide
Commercial partnering opportunities in oncology: a new biomarker test to guide treatment for oestrogen-receptor positive breast cancer 09 Feb 2023 In the first of a series on exciting opportunities for industry to collaborate with scientists at The Institute of Cancer Research, Andrew Czyzewski looks at a new biomarker test developed by Dr Maggie Cheang and colleagues that could guide breast cancer treatment. Find out more Show/Hide
Five reasons why pharma and biotech companies are co-locating with university researchers – and one more reason why you should too! 20 Apr 2022